Targeting vasoactive peptides for managing calcific aortic valve disease

Show full item record



Permalink

http://hdl.handle.net/10138/309277

Citation

Peltonen , T , Ohukainen , P , Ruskoaho , H J & Rysä , J 2017 , ' Targeting vasoactive peptides for managing calcific aortic valve disease ' , Annals of Medicine , vol. 49 , no. 1 , pp. 63-74 . https://doi.org/10.1080/07853890.2016.1231933

Title: Targeting vasoactive peptides for managing calcific aortic valve disease
Author: Peltonen, Tuomas; Ohukainen, Pauli; Ruskoaho, Heikki Juhani; Rysä, Jaana
Contributor organization: Drug Research Program
Regenerative pharmacology group
Division of Pharmacology and Pharmacotherapy
Faculty of Pharmacy
Date: 2017-02
Language: eng
Number of pages: 12
Belongs to series: Annals of Medicine
ISSN: 0785-3890
DOI: https://doi.org/10.1080/07853890.2016.1231933
URI: http://hdl.handle.net/10138/309277
Abstract: Calcific aortic valve disease (CAVD) represents a spectrum of disease spanning from milder degrees of calcification of valve leaflets, i.e., aortic sclerosis, to severe calcification i.e., aortic stenosis (AS) with hemodynamic instability. The prevalence of CAVD is increasing rapidly due to the aging of the population, being up to 2.8% among patients over 75 years of age. Even without significant aortic valve stenosis, aortic sclerosis is associated with a 50% increased risk of myocardial infarction and death from cardiovascular causes. To date, there is no pharmacological treatment available to reverse or hinder the progression of CAVD. So far, the cholesterol-lowering therapies (statins) and renin-angiotensin system (RAS) blocking drugs have been the major pharmacological agents investigated for treatment of CAVD. Especially angiotensin receptor blockers (ARB)s and angiotensin convertase enzyme inhibitors (ACEI)s, have been under active investigation in clinical trials, but have proven to be unsuccessful in slowing the progression of CAVD. Several studies have suggested that other vasoactive hormones, including endothelin and apelin systems are also associated with development of AS. In the present review, we discuss the role of vasoactive factors in the pathogenesis of CAVD as novel pharmacological targets for the treatment of aortic valve calcification.
Subject: 3121 General medicine, internal medicine and other clinical medicine
aortic valve stenosis
apelin
bradykinin
endothelin
natriuretic peptides
renin-angiotensin system
Peer reviewed: Yes
Rights: unspecified
Usage restriction: openAccess
Self-archived version: acceptedVersion


Files in this item

Total number of downloads: Loading...

Files Size Format View
Peltonen_2017_AnnMed_1.pdf 4.318Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record